Diagnostic Kits/The dangers of diagnostic monopolies: Difference between revisions
Jump to navigation
Jump to search
AClearwater (talk | contribs) (added beginning of highlights) |
AClearwater (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
*eight case studies | *eight case studies | ||
**on access to genetic tests for ten conditions (prepared for Secretary’s Advisory Committee on Genetics, Health and Society) | **on access to genetic tests for ten conditions (prepared for Secretary’s Advisory Committee on Genetics, Health and Society) | ||
*Effect of patents | *Effect of patents generally | ||
**not a great harm | **not a great harm | ||
**not a great help | **not a great help | ||
*Effect of patents on price | |||
**tests without a monopoly are priced similarly to tests with a monopoly | |||
Revision as of 11:27, 2 October 2009
Cook-Deegan, R., Chandrasekharan, S. & Angrist, M., 2009. The dangers of diagnostic monopolies. Nature, 458(7237), 405-406.
- "few empirical studies to help form an accurate picture of how patents affect clinical genetic testing"
- eight case studies
- on access to genetic tests for ten conditions (prepared for Secretary’s Advisory Committee on Genetics, Health and Society)
- Effect of patents generally
- not a great harm
- not a great help
- Effect of patents on price
- tests without a monopoly are priced similarly to tests with a monopoly